-

Foundation Medicine Announces Partnership With Epic to Streamline Access to Genomic Insights for Precision Cancer Care

Platform Integration With the Nation’s Largest Electronic Medical Record Provider Will Support Clinicians in Treatment Strategy Decisions and Help Simplify Precision Oncology Orders and Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. today announced a partnership to integrate its comprehensive genomic profiling (CGP) and other testing services with Epic’s electronic medical record (EMR) system. Once completed, all providers who use Foundation Medicine’s instance of Epic will be able to electronically order Foundation Medicine tests within the Epic network. The integration is designed to support oncology practices, academic medical centers and other health systems by providing easy access to clinical and genomic information in one place to better enable more streamlined clinical decision making. This integration is one of many updates Foundation Medicine is making across its portfolio to help expand precision oncology through efficient and high-quality, data-driven insights.

This integration will enable clinical teams to place orders for Foundation Medicine’s CGP tests, and receive and view results directly within their existing workflow in Epic’s EMR platform. The enhancement will also target to reduce data entry with the aim of accelerating delivery of actionable insights to physicians to help guide treatment planning.

“In order to bring the reality of precision medicine to more cancer patients, we need to simplify the process for getting oncologists access to the genomic insights they need for targeted treatment planning,” said Kathleen Kaa, Interim Chief Commercial Officer at Foundation Medicine. “This integration with Epic is one of our key efforts to improve the process for ordering our tests so care teams can focus on providing the best treatment for their patients.”

The integration, expected to be available next year, is an important advancement for precision oncology and data-driven decision making. By integrating test reporting directly into Epic, this effort will help drive clinical workflow efficiency and arm providers with streamlined access to clinical and genomic information in one location. Upon completion of these enhancements, care teams will be empowered with easy access to precision medicine pathways.

Foundation Medicine is also partnering with several institutions using EMR systems other than Epic’s to enable custom EMR solutions for those practices.

About Foundation Medicine

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

Foundation Medicine® is a registered trademark of Foundation Medicine, Inc.

Source: Foundation Medicine

Contacts

Abigail Alderman, 781-534-3210
pr@foundationmedicine.com

Foundation Medicine


Release Summary
Foundation Medicine's Integration With Nation’s Largest Electronic Medical Record Provider Epic to Support Clinicians in Treatment Strategy Decisions.
Release Versions

Contacts

Abigail Alderman, 781-534-3210
pr@foundationmedicine.com

More News From Foundation Medicine

U.S. Food and Drug Administration Approves FoundationOne®CDx as a Companion Diagnostic for Itovebi™ (inavolisib) to Identify Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx to be used as a companion diagnostic for Itovebi™ (inavolisib) in combination with palbociclib (Ibrance®) and fulvestrant. Itovebi is a therapy developed by Genentech, a member of the Roche group, which is approved for the treatment of adult patients with endocrine-resistant,...

Foundation Medicine and SWOG Clinical Trials Partnerships Announce Strategic Collaboration to Advance Biomarker-Driven Research and Clinical Trials

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a global, patient-focused precision medicine company, and SWOG Clinical Trials Partnerships (SWOG CTP) today announced a strategic partnership to advance biomarker-driven research and clinical trials, marking the first collaboration of this nature with a diagnostic company. This partnership builds upon Foundation Medicine’s decade-long collaboration with SWOG Cancer Research Network through the Lung Cancer Master Protocol (Lung-MAP) trial, a m...

US FDA Approves FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for TALZENNA® (talazoparib) in Combination with XTANDI® (enzalutamide) to Identify Patients with HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced that it has received approvals from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx and FoundationOne®Liquid CDx to be used as companion diagnostics for Pfizer’s TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide) to identify patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRP...
Back to Newsroom